Form 4: Lyell CSO Acquires 68,000 Stock Options Under 10b5-1 Plan

Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, acquired 68,000 stock options at an exercise price of $17.23, effective October 27, 2025.

Summary

• Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma, Inc., reported changes in beneficial ownership.
• Lee acquired 68,000 stock options to purchase common stock.
• The exercise price for these options is $17.23 per share.
• The transaction date for the option acquisition was October 27, 2025.
• 12.5% of the option shares will vest on April 27, 2026, with the remainder vesting in equal monthly installments over the subsequent 42 months, subject to continued service.
• The options expire on October 26, 2035.
• Lee also beneficially owns 15,504 shares of common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.

Sentiment

Score: 7

Explanation: The acquisition of a significant number of stock options by a key executive (CSO) suggests management confidence in the company's future prospects and aligns executive incentives with long-term shareholder value. This is generally viewed positively, though it's not a direct cash investment.

Positives

• The acquisition of a significant number of stock options (68,000) by a key executive (Chief Scientific Officer) indicates confidence in the company's future prospects.
• The transaction was executed under a Rule 10b5-1 plan, suggesting a pre-planned, non-discretionary acquisition, which can reduce concerns about opportunistic insider trading.
• The long-term vesting schedule aligns the executive's incentives with the company's sustained performance and shareholder value creation over several years.

Negatives

• This transaction represents an option grant, not a direct cash investment in the company's stock by the executive.
• The value of the options is contingent on the company's stock price exceeding the exercise price of $17.23 in the future.

Risks

• The value of the acquired options is entirely dependent on Lyell Immunopharma's stock price appreciating above the $17.23 exercise price.
• The vesting of the options is subject to the reporting person providing continuous service through the applicable vesting dates, meaning forfeiture could occur if employment ceases prematurely.

Future Outlook

The vesting schedule for the acquired options extends over 42 months following April 27, 2026, indicating a long-term incentive structure for the Chief Scientific Officer, aligning his interests with the company's future performance and strategic goals.

Industry Context

This insider transaction report reflects a common practice in the biotechnology industry where executive compensation packages frequently include stock options to incentivize long-term commitment and innovation. For a research-intensive company like Lyell Immunopharma, retaining key scientific leadership is crucial, and equity-based compensation is a standard tool for this purpose.

Comparison to Industry Standards

• Executive stock option grants are a prevalent compensation tool across the biotechnology and pharmaceutical industries, similar to practices at companies like Gilead Sciences, Amgen, or Moderna, used to retain key talent and align executive interests with shareholder value.
• The vesting schedule (12.5% after 6 months, then monthly over 42 months) is a typical multi-year vesting structure designed to encourage long-term commitment and performance, comparable to equity incentive plans seen at many growth-stage biotech firms.
• The use of a Rule 10b5-1 plan for option acquisition is a standard practice for insiders to avoid accusations of trading on material non-public information, widely adopted across all industries, including biotech.

Stakeholder Impact

• Shareholders: The acquisition of options by the Chief Scientific Officer aligns his long-term interests with shareholder value creation, as the options gain value only if the stock price increases.
• Employees: May signal stability and confidence in the company's leadership and future direction, potentially boosting morale.

Next Steps

• Continued vesting of the 68,000 stock options over the next 42 months, subject to Gary K. Lee's continued service.
• Potential exercise of options by Gary K. Lee if the stock price exceeds the $17.23 exercise price prior to the expiration date.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a key executive as part of their compensation package, executed under a Rule 10b5-1 plan. While it indicates management's long-term alignment with the company's success, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions while awaiting more substantive operational or financial updates.

Keywords

Lyell Immunopharma, LYEL, Stock Options, Insider Transaction, Form 4, Executive Compensation, Gary K. Lee, Chief Scientific Officer, Biotechnology, Immunotherapy, Rule 10b5-1